Navigation Links
Jubilant to Work With Endo Pharmaceuticals on Drug Development
Date:6/11/2009

NOIDA, India, June 11 /PRNewswire/ --

- Collaboration to Provide Endo Pharmaceuticals With New Drug Candidates in Oncology

Jubilant Organosys Ltd., headquartered in Noida, announced today that its Bangalore-based subsidiary, Jubilant Biosys Ltd., has entered into a discovery and development collaboration with Endo Pharmaceuticals, a US-based pharmaceutical company. As part of the agreement, Jubilant and Endo would collaborate initially to develop a portfolio of targets in the area of oncology, with a focus on delivering preclinical candidates that could be selected for joint clinical development.

Endo will own any compounds developed under the collaboration and will be responsible for worldwide commercialization.

Under an initial three-year agreement, Jubilant will receive from Endo research funding and success-based development milestones and royalties on the successful commercialization of the compounds developed.

Endo Pharmaceuticals, is a specialty pharmaceutical company engaged in R&D, sales and marketing of branded and generic medicines in pain management, urology, endocrinology and oncology.

Commenting on the Collaboration, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Organosys Ltd, said: "We are pleased to announce this collaboration with Endo Pharmaceuticals, and look forward to the prospect of contributing to Endo's expanding discovery pipeline. We anticipate significant rewards on successful development of compounds and its subsequent commercialization. This partnership continues to demonstrate Jubilant's mission to be India's largest provider of innovative solutions for accelerating global drug development and enabling affordable patient care."

Dr. Ivan Gergel M.D., Executive Vice President, Research & Development of Endo Pharmaceuticals said: "We are excited about this opportunity with Jubilant. We look forward to our collaboration with the goal of bringing new therapies and healthcare solutions to patients."

About Jubilant Biosys

Jubilant Biosys Ltd. is a subsidiary of Jubilant Organosys Ltd., which provides integrated drug discovery and development solutions to the global pharmaceutical industry. The 120,000 sq. ft. state of the art Jubilant Biosys Discovery Center in Bangalore integrates the capabilities of over 300 scientists specializing in multiple disciplines including biology, chemistry, structural biology, pharmacology, molecular modelling, crystallography and information technology to support collaborations with global pharma companies in USA, Europe and Japan.For more information visit: http://www.jubilantbiosys.com

About Jubilant Organosys

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, is the largest custom research and manufacturing services (CRAMS) and leading drug discovery and development services companies out of India. The company has a presence across the pharmaceutical value chain for products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and healthcare. Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these help Jubilant cater to 150 customers across more than 50 countries around the world.

For more information visit: http://www.jubl.com

Disclaimer:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company's filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.


'/>"/>
SOURCE Jubilant Organosys Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Jubilant Biosys Launches Legend NGSS(TM) Advanced Software Solution for High-Throughput Drug Molecule Screening
2. Jubilant and BioLeap Announce New Partnership in Drug Discovery
3. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
4. ADVENTRX Pharmaceuticals Announces Financing
5. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
6. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
7. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
8. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
9. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
10. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
11. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... June 28, 2017 Michael Zasloff , ... University School of Medicine, and Founder, Chairman and CEO ... study that has helped clarify the function of alpha-Synuclein ... other neurodegenerative diseases. Denise Barbut , MD, FRCP, ... was senior co-author of the study. Published ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... three research projects accepted for presentation at the 33rd Annual Meeting of the ... – including some of the world’s top thought leaders in reproductive medicine – ...
(Date:6/28/2017)... and London, June 28, 2017 (PRWEB) , ... ... ... The latest release of Siemens’ STAR-CCM+® software for multiphysics computational fluid ... enable automated product design exploration and optimization. STAR-CCM+ version 12.04 introduces Design ...
(Date:6/28/2017)... NC (PRWEB) , ... June 28, 2017 , ... Studies ... might lead to an effective treatment for Parkinson’s disease. But what has not been ... should take place to gain the best results. , A new study coming out ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):